AZoLifeSciences on MSN1d
Uncovering Key Differences Between Humans and Mice in Cancer Immunotherapy Targets
Programmed cell death protein 1,” or PD-1, has been considered a key target in cancer therapies since its discovery in the ...
Scientists unveil surprising human vs. mouse differences in a major cancer immunotherapy target
Since its discovery in the 1990s, programmed cell death protein 1 (PD-1) has been regarded as a leading target in cancer ...
C&EN1d
Flawed assumptions could be spoiling cancer immunotherapy research
Cancer immunotherapy drugs called immune checkpoint inhibitors take the brakes off the body’s immune system, allowing it to ...
Breakthrough Discovery Reveals Hidden Flaws in Cancer Research Models
Scientists have discovered significant discrepancies in PD-1 between humans and rodents, indicating that common lab models ...
Business Wire11d
TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today annou ...
Nature1y
Cell death discovery adds fresh angle to attack cancer
Cell death comes in many forms, depending on the trigger. During human embryonic development, for example, cells that make up the webbing between the fingers will undergo an orderly self ...